SINGAPORE (Aug 31): Investors and foreign biotech veterans are making their way to China as the government aims to build a healthcare empire.

Jeremy Yee, former CEO of Cordlife Group and now running his second healthcare company Clearbridge Health, hopes to tap into that optimism. He plans to spin off a cancer diagnostics associate company that is aiming to expand into China, and buy more testing laboratories in the region. Yee hopes these moves will help revive investor interest in Clearbridge.

The company was listed last December; its shares hit 63 cents on Feb 1, but have since fallen more than 62% to close at 24 cents on Aug 30 and 14% below its IPO price of 28 cents.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook